GPLD1 anticorps (AbBy Fluor® 594)

N° du produit ABIN2813949

Détail du produit anti-GPLD1 anticorps (AbBy Fluor® 594)

Antigène: GPLD1 (Glycosylphosphatidylinositol Specific phospholipase D1 (GPLD1))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp GPLD1 est conjugé à/à la AbBy Fluor® 594

Application: Western Blotting (WB), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Réactivité croisée: Humain, Souris, Rat

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human GPLD1/GPI-PLD

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur GPLD1

Antigène: GPLD1 (Glycosylphosphatidylinositol Specific phospholipase D1 (GPLD1))

Autre désignation: GPLD1 (GPLD1 Produits)

Sujet:

Synonyms: Glycoprotein phospholipase D, Glycosyl-phosphatidylinositol-specic phospholipase D, GPI-PLD, GPI-specic phospholipase D, GPIPLD, GPIPLDM, GPLD1, PHLD_HUMAN, Phosphatidylinositol glycan specic phospholipase D, Phosphatidylinositol-glycan-specic phospholipase D, PI-G PLD, PIGPLD, PIGPLD1.

Background: Phosphatidylinositol-glycan-specific phospholipase D (GPI-PLD) is a high-density lipoprotein-associated protein found on chromosome 6p22 that specifically hydrolyzes the inositol phosphate linkage in proteins anchored by phosphatidylinositol-glycans (PI-Gs). GPI-PLD is found in serum, liver, cerebrospinal fluid and in milk. The majority of plasma GPI-PLD appears to be specifically associated with a small, discrete and minor fraction of lipoproteins containing apoA-I and apoA-IV. Serum GPI-PLD activity is reduced over 75 % in systemic inflammatory response syndrome and the downregulation of GPI-PLD could play an important role in the control of proinflammatory responses.

ID gène: 2822

Pathways: Inositol Metabolic Process, Regulation of Carbohydrate Metabolic Process